Rationale: Exacerbations are key events in the natural history of bronchiectasis, but clinical predictors and outcomes of patients with frequently exacerbating disease are not well described.
Bronchiectasis is a clinical syndrome defined by abnormal, usually permanent dilatation of the bronchi associated with cough and sputum production (1) . In addition, for many patients the daily symptoms of the disease are accompanied by unpredictable worsening of symptoms greater than the normal day-to-day variation and referred to as exacerbations (2, 3) .
Exacerbations are recognized as important events in the natural history of bronchiectasis. International guidelines for bronchiectasis recommend treatment with, for example, inhaled or oral prophylactic antibiotic therapy for patients with three or more exacerbations per year, with the aim of preventing exacerbations (4) (5) (6) . Exacerbations form part of the bronchiectasis severity index (BSI), a multidimensional severity assessment tool for bronchiectasis (7) . In addition, exacerbation frequency or the time to first exacerbation has been the primary endpoint for the majority of phase 3 randomized clinical trials in bronchiectasis (8) (9) (10) (11) .
It is surprising, therefore, that there have been few published studies describing the frequency of exacerbations over time and risk factors for exacerbations in bronchiectasis. Bronchiectasis is a highly heterogeneous disease in terms of etiology, severity, and clinical outcomes (1-7). Exacerbation frequency is no different, and patient characteristics vary, with reported frequency of exacerbations across different populations ranging from zero to nine events per patient per year (1) .
In clinical practice, it is important to identify patients who are at risk of future exacerbations to target preventative therapies appropriately. For research, it is important to identify patients likely to have future exacerbations to adequately power clinical trials (7) (8) (9) (10) (11) . In chronic obstructive pulmonary disease (COPD), Hurst and colleagues identified a frequent exacerbator "phenotype" by demonstrating that over a 3-year period, exacerbation frequency showed a relative degree of stability (12) . An accepted definition of phenotypes for COPD originally proposed by Han and colleagues requires "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death)" (13) . This definition can also be applied to patients with bronchiectasis (13, 14) . Thus, to be a valid patient phenotype in bronchiectasis, the "frequent exacerbator" should show stability over time and should be linked to clinically meaningful outcomes, such as quality of life (QoL), future exacerbations, disease progression, and/or death.
In this study, we used a European patient cohort to determine whether frequent exacerbator status was stable over time and to determine its relationship with clinical outcomes. Some of the results of this study have previously been reported as an abstract (15) .
Methods
We analyzed data from patients with bronchiectasis enrolled in 10 different bronchiectasis clinical centers across Europe (including Israel as a European Union-affiliated country) (Dundee, Edinburgh, and Newcastle, UK; Haifa, Israel; Galway, Ireland; Leuven, Belgium; Athens, Greece; Monza, Italy; Barcelona, Spain; and Vojvodina, Serbia) between 2007 and 2013. Details of this cohort have been described previously (16, 17) . Inclusion criteria were: consecutive patients aged 18 years or older, diagnosis of bronchiectasis made by a specialist physician, high-resolution computed tomographic scan, and a clinical history consistent with bronchiectasis. Exclusion criteria were: cystic fibrosis, traction bronchiectasis due to pulmonary fibrosis, and active nontuberculous mycobacterial disease.
Local ethics committees or institutional review boards approved the data collection at each site. Diagnostic work-up and assessment were made following the 2010 British Thoracic Society guidelines (6) .
Baseline data collection was performed when patients were clinically stable and free from antibiotic therapy for exacerbations for a minimum of 4 weeks. Chronic infection was defined by isolation of the same pathogen in two or more cultures, at least 3 months apart in a 12-month span, with the patient in stable state (18) . A core dataset consisting of demographics, previous medical history, comorbidities, as well as radiological, laboratory and microbiological findings was recorded at each site. QoL was measured by the St. Georges Respiratory Questionnaire (SGRQ), and severity of disease was evaluated by the BSI (7). Prophylactic antibiotic therapy at baseline was defined as administration of antibiotics with prophylactic intention, rather than for treatment of an exacerbation, for at least 28 days before baseline.
For the purposes of analysis, three or more exacerbations per year were regarded as frequent exacerbations on the basis of the European Respiratory Society bronchiectasis guidelines (4) , and patients were subdivided by a history of zero, one, 
Outcomes
Outcomes were evaluated for up to 5 years of follow-up. Outcomes were: all-cause mortality; exacerbations: defined as the requirement for antibiotics in the presence of one or more symptoms of increasing cough, increasing sputum volume, worsening sputum purulence, worsening dyspnea, increased fatigue/malaise, fever, and hemoptysis; and severe exacerbations: defined according to British Thoracic Society guidelines as unscheduled hospitalizations or emergency department visits for exacerbations or complications as recorded from patient histories and verified using administrative databases (6) .
Exacerbations were recorded for 12 months after the first visit in all patients and for 3 years in a subset.
Statistical Analysis
Descriptive statistics of median with 25 to 75% interquartile range were used for continuous data and absolute frequencies and percentages for categorical data. Subgroup comparisons were performed using the Mann-Whitney U test or chi-square test, depending on data type. A comparisonwise significance level of 5% was used.
To determine independent predictors of future exacerbation frequency, we used a negative binomial model with adjustment for length of follow-up time. Results are reported as incident rate ratios (IRRs) with 95% confidence intervals (CIs). For multivariable mortality analysis, a multivariable Cox regression analysis was used. The proportional hazards assumption was checked by inspection of log minus log plots. Variables included in the model were those determined to be clinically significant in impacting on mortality. Multivariable analysis of binary outcomes was performed using multivariable logistic regression. The accuracy of prior exacerbations to predict future exacerbations was reported using sensitivity and specificity and associated likelihood ratios. Discrimination was assessed by the area under the receiver operator characteristic (ROC) curve. A multiple linear regression model was applied to determine the variables with independent impact on QoL. All analyses were performed using SPSS version 21 for Windows and Graph Pad Prism Version 5 (Graph Pad Software, Inc.).
Results

Patient Characteristics
The study population was composed of 2,596 patients. The median age was 67 years (interquartile range, 57-74 yr), 38.9% were men, and 61.9% of patients were never smokers. Further patient characteristics are shown in Table 1 . The etiologies of bronchiectasis were typical of European cohorts, with most patients classified as idiopathic (42%), with postinfective etiology (17%), COPD (9%), asthma (6%), connective tissue diseases (6%), and allergic bronchopulmonary aspergillosis (5%) also being common underlying causes.
The patient disposition in the study is shown in Figure 1 . The median exacerbation frequency before the study baseline was two per year. Exacerbation history was not recorded in 24 subjects. In the remaining 2,572 patients, 657 (25.3%) patients had no exacerbations, 452 (17.4%) had one exacerbation, 497 (19.1%) had two exacerbations, and 966 (37.2%) patients had three or more exacerbations. A total of 25.9% of patients had at least one hospital admission for a severe exacerbation before the study. Table 1 shows the characteristics of patients according to their previous exacerbation history. A number of characteristics were statistically significantly different between groups at baseline. Reported P values in Table 1 should be interpreted with caution in view of the multiple comparisons performed.
Consistency of the frequent exacerbator phenotype over time. In the full analysis set, we examined the association between prior exacerbations and future exacerbation events. Compared with patients with zero exacerbations at baseline, the IRR for future exacerbations was 1.73 (95% CI, 1.47-2.02; P , 0.0001) for one exacerbation per year, 3.14 (95% CI, 2.70-3.66; P , 0.0001) for two exacerbations, and 5.97 (95% CI, 5.27-6.78; P , 0.0001) for patients with three or more exacerbations per year, indicating that increasing exacerbations at baseline were associated with higher rates of exacerbation during follow-up.
We next examined the ability of prior exacerbations to predict exacerbations in the following year (Year 1 of follow-up). A history of three or more exacerbations in the previous year predicted three or more exacerbations in the following year with a sensitivity of 79.9% (95% CI, 76.5-83.0%), specificity of 75.8% (95% CI, 73.9-77.7%), negative predictive value of 92.3% (95% CI, 90.8-93.5%), positive predictive value of 51.1% (95% CI, 47.9-54.3%), positive likelihood ratio of 3.31 (95% CI, 3.03-3.61), and negative likelihood ratio of 0.26 (95% CI, 0.23-0.31). The area under the ROC curve for prior exacerbations to predict three or more exacerbations in the following year was 0.83 (95% CI, 0.81-0.85; P , 0.0001).
Equivalent data for a history of two or more exacerbations per year to identify patients having two or more exacerbations in Year 1 were the following: sensitivity 82.6% (95% CI, 80.2-84.6%), specificity 68.1% (95% CI, 65.5-70.6%), positive predictive value 70.3% (95% CI, 67.9-72.7%), negative predictive value 81.0% (95% CI, 78.5-83.2%), positive likelihood ratio 2.59 (95% CI, 2.38-2.81), and negative likelihood ratio 0.26 (95% CI, 22.6-29.0). The area under the ROC curve was 0.76 (95% CI, 0.74-0.78; P , 0.0001). These data suggest a high degree of agreement between baseline and first-year exacerbation frequency.
A total of 1,236 patients had complete data for 4 years of exacerbation recording, including the frequency of exacerbations in the year before the study and for 3 years prospectively. Excluded patients were those who died during follow-up and any patient lost to follow-up. Patients with complete follow-up data therefore tended to have milder disease, with fewer comorbidities (Tables E1 and E2 in the online supplement show the proportion of patients lost to follow-up in each group).
Using this cohort, Figure 2 demonstrates the repeatability of exacerbation frequency over time. It demonstrates a clear relationship between prior exacerbation history and future risk even up to Year 3. The proportion of patients who had three or more exacerbations at baseline and had three or more exacerbations in each year of the study was 24.0% of those with three or more events at baseline and 6.7% overall. The proportion of patients that experienced no exacerbations through all 4 years of exacerbation recording was 23.1% of those with zero events at baseline and 8.2% of patients overall.
To understand variation in exacerbation frequency, we used multivariable logistic regression to examine factors associated with a change in exacerbation status. 
,0.0001 Exacerbations in the previous year Table 2 . Sensitivity analyses adjusting for additional findings were consistent with this primary analysis and are shown in Table E4 .
The clear relationship between prior and future exacerbations remained significant in subgroups with mild, moderate, and severe bronchiectasis (Table  E4) . Patients with a history of severe exacerbations were at higher risk of all exacerbations during follow-up (IRR, 1.43; 95% CI, 1.26-1.63; P , 0.0001). Considering a history of severe and nonsevere exacerbations separately made no difference to the overall conclusions (Table E4) .
Impact of exacerbation history of morbidity and mortality. Patients with frequent exacerbations at baseline had worse health status as measured by the SGRQ (Figure 3) . Differences between all groups were greater than the 4-point minimum clinically important difference, except for the difference between patients with zero and one exacerbation per year at baseline. The scores were 32.5 (18.1-48.8) for patients with zero exacerbations, and 35.9 (22.9-55.3), 44.0 (29.8-87.4), and 59.0 (37.7-74.9) for those with one, two, and three or more exacerbations per year at baseline, respectively (P , 0.0001). Patient QoL was worse in patients with frequent exacerbations across all domains of the SGRQ (P , 0.0001), and this is shown in Figure E1 .
In a multivariable linear regression model, after adjustment for multiple confounders as listed in Table 2 , each additional exacerbation per year was associated with an independent 3.7-point increase in SGRQ total score (95% CI, 2.58-4.87; P , 0.0001). Separating hospitalized and nonhospitalized exacerbations, the equivalent data were a 1.4-point increase for each individual outpatient exacerbation (95% CI, 0.57-2.07; P = 0.001) and a 9.8-point increase in those with a history of hospitalized exacerbations (95% CI, 6.28-13.3; P , 0.0001).
The number of hospital admissions was also greater for those with three or more exacerbations in the previous year (40% of patients were hospitalized during follow-up) than those with two (20.3%), one (11.3%), or zero (11.1%) exacerbations at baseline (P , 0.0001 across groups; Figure 4) .
Mortality was increased in patients with three or more exacerbations per year (Figure 4) . In a Cox proportional hazard regression adjusting for relevant confounding variables, compared with patients with zero exacerbations at baseline, the hazard ratios (HRs) for mortality were 0.92 (95% CI, 0.57-1.48; P = 0.7) for patients with one exacerbation, 1.60 (95% CI, 1.06-2.42; P = 0.03) for patients with two exacerbations, and 1.86 (95% CI, 1.30-2.66; P = 0.001) for patients with three or more exacerbations per year. Therefore, patients with two or more exacerbations per year at baseline have an independent increase in mortality risk.
Examining hospitalized and nonhospitalized exacerbations separately, the unadjusted and adjusted HRs were 3.24 (95% CI, 2.56-4.09; P , 0.0001) and 1.97 (95% CI, 1.51-2.57; P , 0.0001), respectively, for hospitalized exacerbations. For outpatient exacerbations only, the hazard ratios were consistent with the primary analysis, with HR 0.83 (95% CI, 0.53-1.31; P = 0.4) for one exacerbation, 1.45 (95% CI, 0.98-2.16; P = 0.06) for two exacerbations, and 1.53 (95% CI, 1.04-2.25; P = 0.03) for three or more exacerbations.
Sensitivity analysis: consistency of exacerbation frequency by center and the impact of long-term antibiotic treatment.
We finally investigated whether the consistency of the frequent exacerbator phenotype was a universal finding across European centers and whether it was impacted by prior or newly initiated prophylactic antibiotic therapy. The results are shown in Table 3 . The precision of estimates varied across centers because of sample size, but the models indicated increasing future risk of exacerbations with increasing prior exacerbations in all countries. The area under the curve values ranged from 0.73 to 0.93, but all showed good to excellent discrimination of prior exacerbations for future exacerbations.
Patients receiving prior antibiotic therapy had a higher frequency of exacerbations at baseline and during followup (mean, 3.5/yr [SD, 2.5/yr] at baseline and 2.3/yr [SD, 1.9/yr] during follow-up), as reflected in the higher rate ratios for future exacerbations in Table 2 , than patients not receiving prophylactic antibiotics at baseline (1.9 [SD, 2.2]) and follow-up (1.6 [SD, 1.6] ). These data also show the trend for exacerbation frequency to reduce over time.
We conducted a further sensitivity analysis examining the exacerbation frequency in 203 patients who newly commenced prophylactic antibiotic therapy during follow-up, which is known to impact future risk of exacerbation in clinical trials (1, 8) . Data on patients newly commencing prophylactic antibiotic treatment were only available in five cohorts (Dundee, Newcastle, Edinburgh, Haifa, and Leuven). These patients had a mean exacerbation rate of 4.1 (SD, 3.1) before therapy, reducing to 2.0 (SD, 1.9) after therapy. Table 3 shows that despite this apparent response in terms of reduction in exacerbations, patients with a higher exacerbation frequency at baseline still had a higher rate of exacerbations during follow-up. Finally, because the frequent exacerbator phenotype has already been described in COPD, we conducted a sensitivity analysis excluding patients with coexisting COPD. These results are shown in Table 3 and identified very similar estimates to the overall analysis.
Discussion
The objective of this study was to establish if the frequent exacerbator was a valid and clinically important phenotype in bronchiectasis (19) . Recognition of a frequent exacerbator phenotype in COPD linked to poorer health status, lung function decline, and mortality has had a major impact on clinical care and clinical trial design (20) (21) (22) (23) (24) .
To qualify as a phenotype, the characteristic or group of characteristics being studied should be measurable, consistent over time, and linked to clinically relevant outcomes (13) . Our results suggest that the frequent exacerbator phenotype meets these criteria, as exacerbation frequency showed relative stability over time, particularly in those with three or more exacerbations per year at baseline. Exacerbations were associated with an increased risk of death and an independent increase in the SGRQ, suggesting an independent contribution to impaired health status, and were also linked to hospital admissions during follow-up.
Our findings are clinically important because exacerbation reduction is one of the key goals of bronchiectasis management (4) (5) (6) . Our data suggest that without intervention, patients with frequent exacerbations are likely to continue to exacerbate frequently and that this will have 657  654  600  554  522  153  452  444  402  381  351  134  497  490  437  407  376  196  966  958  836  771  694  365   0  1  2  3 or more Numbers at risk ORIGINAL ARTICLE negative consequences for QoL, healthcare use, and mortality. This strengthens the arguments in favor of the use of therapies that have been shown to reduce exacerbations, including macrolides, inhaled antibiotics, mucoactive therapies, and pulmonary rehabilitation (25) (26) (27) . Data from the European and United States bronchiectasis registries suggest that despite a high burden of exacerbations, use of such therapies is low (28) (29) (30) . In the present cohort, 37% of patients had three or more exacerbations per year, but only one-third were receiving prophylactic antibiotic therapies. It is acknowledged that the evidence base for most of these interventions remains weak. Our data also indicate the need for high-quality randomized trials to prove conclusively that such therapies can reduce exacerbations (25) (26) (27) .
Existing published data support the importance of exacerbations as an endpoint in bronchiectasis. They are a major contributor to healthcare costs, and severe exacerbations have been linked to accelerated lung function decline (31) . Exacerbations form part of the multidimensional BSI, which has been validated internationally as a predictor of outcome in patients with bronchiectasis (7) . Several recent comparisons between the BSI and the similar FEV 1 /age/colonization/ extension/dyspnoea (FACED) score found that FACED did not accurately predict future risk of exacerbations, suggesting that it was not a valid predictor of severity of disease (16, 32) . The major difference between the scores is that BSI incorporates history of exacerbations that are not included in FACED (16, 32) . Modification of the FACED to include a past history of exacerbations has been shown to improve its prediction of exacerbations (33) . Our analysis explains why, because overwhelmingly the strongest predictor of future exacerbations is a prior history of exacerbations. Our data suggest that exacerbation history alone, without incorporating other variables, is sensitive and specific for predicting future events, so clinicians can use prior history for clinical decision making with a high degree of confidence.
Our study was not designed to demonstrate why patients exacerbate, so our study does not imply that all patients with three or more exacerbations per year are the same. Most exacerbations of bronchiectasis are believed to be caused by bacterial infection, but there is also evidence that exacerbations are associated with viral infections (34) . Other identified risk factors for exacerbations include elevated sputum neutrophil elastase activity (35) , genetic polymorphisms such as FUT2 (fucosyltransferase 2) (36) and mannose-binding lectin (37) , and multiple comorbidities (17) . Within the frequent exacerbator "phenotype" there may be multiple endotypes, biological subgroups with different patterns of bacteriological, inflammatory, or genetic susceptibility to exacerbation (38, 39) . Future studies should aim to examine and better defined these endotypes now that the clinical phenotype has been clearly established (39) .
Our study has limitations. Exacerbations are poorly defined clinical entities in bronchiectasis, and our study was conducted before the standardization of the definition of exacerbations by a European Bronchiectasis Registry/Bronchiectasis Research Registry task force (2) . Hence, variations in antibiotic use in different countries may impact the frequency of reported events. Our definition of severe exacerbations requires admission to a hospital and may be affected by the availability of home intravenous antibiotic treatments in some countries (40) . Mild exacerbations not receiving antibiotic therapy but requiring an increase in the use of interventions like chest physiotherapy or inhaled therapies are not yet a widely accepted concept in bronchiectasis but have been shown to be important to clinical outcomes in COPD (41, 42) . Future studies should attempt to address whether such events are important in bronchiectasis. For clinical trials, our data suggest that a history of exacerbations can be used to reliably identify a cohort of patients with future exacerbations to power trials where the primary outcome is the frequency of exacerbations. Recent trials recruiting patients with a history of two or more exacerbations per year have observed a relatively low rate of exacerbations during follow-up. There are many possible reasons for this, including the tendency for patients with milder disease to agree to enrollment in clinical trials and differences in the methods used to collect prior exacerbation history and follow-up exacerbation frequency (43) . Our data suggested that a history of three or more exacerbations had an optimal sensitivity and specificity for predicting future events, and future trials may wish to consider using this in their inclusion criteria.
In conclusion, patients with frequently exacerbating bronchiectasis represent a distinct clinical phenotype with different patient characteristics, a high risk of hospital admissions, poor QoL, and a higher risk of death during follow-up. This study emphasizes the importance of prioritizing exacerbation reduction in the management of bronchiectasis. n
